Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

NCT04962425 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04962425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04962425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Lead sponsor
Peking University Third Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 8, 2021
Completion date
December 30, 2021
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antitumor drugs, breast cancer, cardiac toxicity